Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF

Anniina Koski, Lotta Kangasniemi, Sophie Escutenaire, +22

Molecular Therapy

Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

Tuuli Ranki, Sari Pesonen, Akseli Hemminki, +23

Journal for ImmunoTherapy of Cancer

Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Sari Pesonen, Iulia Diaconu, Lotta Kangasniemi, +17

Cancer Research

ImmunologyImmunoeditingImmunodominanceCd4 T Cell ResponsesImmunotherapeutics +21

Tissue-Specific Promoters Active in CD44+CD24−/low Breast Cancer Cells

Gerd Bauerschmitz, Tuuli Ranki, Lotta Kangasniemi, +12

Cancer Research

Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer

Mari Raki, Anna Kanerva, Ari Ristimäki, +6

Gene Therapy

Molecular BiologyCancer Cell BiologyCancer TreatmentMedicineCell Biology +3

Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses

Kilian Guse, Tuuli Ranki, Martti Ala‐Opas, +6

Molecular Cancer Therapeutics

Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus

Anna Kanerva, Kurt R. Zinn, K-W Peng, +11

Gene Therapy

ImmunologyPathologyVivo MonitoringViral OncologyMedicine +5

Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8⁺T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer

Lotta Vassilev, Tuuli Ranki, Timo Joensuu, +22

OncoImmunology

Synergistic anti‐tumor efficacy of immunogenic adenovirus ONCOS‐102 (Ad5/3‐D24‐GM‐CSF) and standard of care chemotherapy in preclinical mesothelioma model

Łukasz Kuryk, Elina Haavisto, Mariangela Garofalo, +6

International Journal of Cancer

A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Δ24, for the treatment of advanced breast cancer

Tuuli Ranki, Anna Kanerva, Ari Ristimäki, +7

Gene Therapy

Advanced Breast CancerImmunologyReplicative AdenovirusMedicineRadiation Oncology +4